Trial Profile

Multicenter Open-Label Single-Arm Trial of the Efficacy and Safety of BCD-100 in Combination With Platinum-Based Chemotherapy and Bevacizumab as First Line Treatment in Patients With Recurrent, Persistent or Metastatic Cervical Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Prolgolimab (Primary)
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms CAESURA
Sponsors Biocad

06 Jun 2023 Status changed to completed as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2023 Final results assessing the efficacy and safety of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
15 Apr 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com